BMS

Thirteen leading pharma companies released second-quarter 2021 financial results in July, while one Japanese firm reported first-quarter results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
 
Pfizer’s revenues soared 86% in the second quarter to $19 billion, beating consensus estimates of $17.5 billion. The Comirnaty Covid-19 vaccine led the results with $7.8 billion in sales. Based on contracts signed through mid-…

The state of the hunt: 

China authorized Sinovac’s vaccine for children as young as age 3.
  The U.S. will reportedly divert $2 billion from COVAX to pay Pfizer/BioNTech for doses it intends to donate.
  Merck entered a $1.2 billion deal to supply an investigational antiviral to the U.S., pending a regulatory nod.   Approved or authorized vaccines

China cleared Sinovac’s CoronaVac jab for youths ages 3 to 17, becoming the first country to offer Covid-19 vaccines to…

Twelve leading pharma companies released first-quarter 2021 financial results in April. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Abbott’s first-quarter worldwide sales jumped 32.9% over last year’s to $10.5 billion, missing consensus estimates by 3.5%. Its diagnostics business continued to boom, with strong Covid-19 test sales driving 115% growth. The company said it has delivered nearly 700 million Covid-19 tests since the start of the…

Oxford-based Exscientia announced Monday that it has raised $225 million in Series D financing and up to $300 million in an equity investment from the SoftBank Vision Fund 2, which led the round. The AI-driven company will use the funds to advance its proprietary pipeline through clinical testing and expand its technology platform toward “autonomous drug design,” the press release said.

Bristol Myers Squibb, Farallon Capital and Novo Holdings also contributed to the round. Exscientia…

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Twelve leading pharma companies released fourth-quarter and full-year 2020 financial results in February. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Gilead’s fourth-quarter revenue soared 26% over last year to $7.4 billion, beating consensus estimates by 4%. Veklury (remdesivir) drove the surge with $1.9 billion in quarterly sales: the antiviral now treats one in two hospitalized Covid-19 patients in the United States, according to the…

Basel-based Lonza announced Monday that it will sell its specialty ingredients division to private equity firms Bain Capital and Cinven for $4.7 billion, allowing the CDMO to “refocus its business” on the healthcare industry, according to its press release.

In other CDMO news, Shanghai-based WuXi AppTec subsidiary WuXi STA announced last week that it will buy Bristol Myers Squibb’s tablet and capsule manufacturing facility in Couvet, Switzerland for an undisclosed price. WuXi AppTec’s…

Mentions:

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

For the seventh time in a row, GSK topped the Access to Medicine (AtM) Foundation’s ranking of leading pharma companies’ efforts to provide access to their products in low- and middle-income countries, according to the 2021 AtM Index, launched Tuesday. But the new index showed Novartis gaining on GSK compared to 2018—with the difference in scores falling to only 1.2%.

Overall, 17 of the 20 companies in the index improved their assessments, with Pfizer climbing the most to join the…

Covid-19 dominated the 39th J. P. Morgan Healthcare Conference (JPM), held virtually this week instead of at its customary haunt, San Francisco’s Westin St. Francis. Beyond much coronavirus chatter, the event also featured one major M&A announcement (Sanofi touting its $1 billion Kymab buy) and additional vaccine news from companies including GSK (for RSV), Moderna (for flu, HIV and Nipah) and Takeda (for dengue).

BioNTech CEO Uğur Şahin announced the German company’s plans to…